Amid rising COVID-19 coronavirus cases worldwide, US-based biotech firm Moderna is getting closer to releasing data on its late-stage trials of the coronavirus vaccine candidate. .
Moderna has announced that it has collected enough data for an interim analysis of the last stage of the trial of its coronavirus vaccine, adding that the analysis of the data will help the company discover the efficacy of the vaccine. According to the US company, the information is being prepared for presentation to the independent data security monitoring board, which is tasked with analyzing the results and making recommendations, but Moderna has not yet announced the date for the release of the data. efficacy data of the coronavirus vaccine candidate.
On Monday, Pfizer Inc. and BioNTech SE said Monday that their vaccine candidate was found to be more than 90 percent effective in preventing COVID-19. “Today is a great day for science and humanity. The first set of results from our Phase 3 COVID-19 vaccine trial provides initial evidence of our vaccine’s ability to prevent COVID-19,” said the President and Director. Pfizer executive Albert Bourla.
Meanwhile, AIIMS Director Dr. Randeep Guleria said on Wednesday (November 11) that the extremely low temperature of minus 70 degrees Celsius required to store a potential COVID-19 vaccine developed by Pfizer represents a major challenge for its delivery in India, especially in its smaller cities and rural areas where it is not easy to maintain such cold chain facilities.
Read: Unlock 5.0: This Status Postpones Decision to Reopen Schools for Classes 9-12 Nov 16
Most vaccines in India should be stored at a temperature of two to eight degrees Celsius. The lowest minimum temperature at which vaccines can be kept to maintain the cold chain in most areas of the country is minus 25 degrees Celsius, Guleria said.
.
